Meningococcal is a deadly disease is not taken care of immediately. The disease is majorly present in the teenage group and is caused by bacterial meningitis. It is basically an inflammation lining of the brain and spinal cord. There are three types of vaccines available for meningitis one of which is sold as menomune, menactra, and Bexsero and Trumenba. Annually, 2000-2600 teenagers are affected from this disease. Among these, one third are young adults, other 10% of the population from this disease are probable to lose their lives even after taking the antibiotic treatment. The remaining 20% of the population with this disease may experience permanent side-effects, such as brain damage and hearing loss.
Increasing number of initiatives for development of novel vaccines by government bodies, international health organizations, private sectors and public health bodies has played a crucial role in promoting the growth of meningococcal vaccines market. For instance, from April 2019, Australian Government announced Nimenrix (MenACWY vaccine) to be funded as part of the National Immunization Program (NIP) for adolescents. Moreover, novel vaccines targeting different serogroups of meningococci are receiving approvals for sales in different regions, which in turn is contributing in the growth of the market. For instance, on 30 May 2017, Pfizer Inc. received European Commission (EC) for TRUMENBA (Meningococcal Group B Vaccine). TRUMENBA aids in prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) among individuals 10 years of age and older. However, the strict storage conditions required for meningococcal vaccines, adds on to the cost, which in turn hampers the growth of the market.
Major Key Players of the Meningococcal Vaccines Market are:GlaxoSmithKline , Sanofi, Pfizer, Serum Institute of India Pvt. Ltd, Nuron Biotech Inc., BIO-MED, Hualan Biological Engineering Inc, Walvax Biotechnology Co., Ltd. and other key players (if any) among others.
Read More @ https://www.openpr.com/news/2036123/meningococcal-vaccines-market-share-forecast-to-witness
Increasing number of initiatives for development of novel vaccines by government bodies, international health organizations, private sectors and public health bodies has played a crucial role in promoting the growth of meningococcal vaccines market. For instance, from April 2019, Australian Government announced Nimenrix (MenACWY vaccine) to be funded as part of the National Immunization Program (NIP) for adolescents. Moreover, novel vaccines targeting different serogroups of meningococci are receiving approvals for sales in different regions, which in turn is contributing in the growth of the market. For instance, on 30 May 2017, Pfizer Inc. received European Commission (EC) for TRUMENBA (Meningococcal Group B Vaccine). TRUMENBA aids in prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) among individuals 10 years of age and older. However, the strict storage conditions required for meningococcal vaccines, adds on to the cost, which in turn hampers the growth of the market.
Major Key Players of the Meningococcal Vaccines Market are:GlaxoSmithKline , Sanofi, Pfizer, Serum Institute of India Pvt. Ltd, Nuron Biotech Inc., BIO-MED, Hualan Biological Engineering Inc, Walvax Biotechnology Co., Ltd. and other key players (if any) among others.
Read More @ https://www.openpr.com/news/2036123/meningococcal-vaccines-market-share-forecast-to-witness
No comments:
Post a Comment